NYSE:ZBH - Zimmer Biomet Stock Price, News, & Analysis

Get Started

$112.40 -1.10 (-0.97 %)

(As of 11/20/2018 04:00 PM ET)

Previous Close$113.50

Today's Range$110.77 - $113.07

52-Week Range$104.28 - $134.55

Volume1.16 million shs

Average Volume1.17 million shs

Market Capitalization$23.88 billion

P/E Ratio14.00

Dividend Yield0.82%

Beta1.16

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:ZBH

Previous SymbolNYSE:ZMH

CUSIPN/A

Webwww.zimmerbiomet.com

Phone574-267-6131

Debt

Debt-to-Equity Ratio0.70

Current Ratio1.89

Quick Ratio0.96

Price-To-Earnings

Trailing P/E Ratio14.00

Forward P/E Ratio14.69

P/E Growth2.37

Sales & Book Value

Annual Sales$7.82 billion

Price / Sales2.93

Cash Flow$14.3734 per share

Price / Cash7.82

Book Value$57.96 per share

Price / Book1.94

Profitability

EPS (Most Recent Fiscal Year)$8.03

Net Income$1.81 billion

Net Margins22.42%

Return on Equity12.88%

Return on Assets5.95%

Miscellaneous

Employees18,200

Outstanding Shares203,980,000

Market Cap$23.88 billion

OptionableOptionable

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet announced a quarterly dividend on Thursday, September 13th. Investors of record on Friday, September 28th will be given a dividend of $0.24 per share on Wednesday, October 31st. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date is Thursday, September 27th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) released its quarterly earnings data on Friday, October, 26th. The medical equipment provider reported $1.63 EPS for the quarter, beating the consensus estimate of $1.60 by $0.03. The medical equipment provider had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.84 billion. Zimmer Biomet had a net margin of 22.42% and a return on equity of 12.88%. The business's revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.72 earnings per share. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Tuesday, January 29th 2019. View Earnings Estimates for Zimmer Biomet.

What price target have analysts set for ZBH?

22 analysts have issued twelve-month price objectives for Zimmer Biomet's stock. Their forecasts range from $96.00 to $168.00. On average, they expect Zimmer Biomet's stock price to reach $134.6316 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 2 sell ratings, 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:

1. According to Zacks Investment Research, "Zimmer Biomet ended the quarter on a mixed note. While earnings and revenues surpassed the consensus estimate, the year-over-year decline in adjusted EPS is a concern. We believe escalating costs and expenses are exerting considerable pressure on the bottom line. Also, declining dental sales at CER is a drag. Adverse currency movements continue to remain a major headwind for Zimmer Biomet. In the past three months, the company has underperformed its industry. On the brighter side, the company’s consistent efforts in product and renovation through research and development raise hopes. Improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its focus on priority areas like quality remediation, supply recovery efforts and product launches, Zimmer Biomet reported strong top-line numbers within its S.E.T arm." (11/17/2018)
2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)
3. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018)
4. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018)

Has Zimmer Biomet been receiving favorable news coverage?

News stories about ZBH stock have trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zimmer Biomet earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the company's share price in the immediate future.

Who are some of Zimmer Biomet's key competitors?

Some companies that are related to Zimmer Biomet include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Smith & Nephew (SNN), Steris (STE), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX) and Invacare (IVC).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:

Mr. Bryan C. Hanson, Pres, CEO & Director (Age 51)
Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 54)
Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 46)
Mr. Sang Yi, Pres of Asia Pacific (Age 56)
Mr. Kenneth R. Tripp, Sr. VP of Global Operations & Logistics

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.75%), Massachusetts Financial Services Co. MA (6.85%), JPMorgan Chase & Co. (5.68%), Longview Partners Guernsey LTD (3.23%), American Century Companies Inc. (2.17%) and Nordea Investment Management AB (2.02%). Company insiders that own Zimmer Biomet stock include Bryan C Hanson, Chad F Phipps, David A Jr Nolan, David C Dvorak, Katarzyna Mazur-Hofsaess, Sang Yi and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which institutional investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Massachusetts Financial Services Co. MA, Renaissance Technologies LLC, American Century Companies Inc., The Manufacturers Life Insurance Company , Morgan Stanley, Deutsche Bank AG and Cannell Peter B & Co. Inc.. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.

Which institutional investors are buying Zimmer Biomet stock?

ZBH stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., OppenheimerFunds Inc., BlackRock Inc., Primecap Management Co. CA, Point72 Asset Management L.P., Tavio Capital LLC, TIAA CREF Investment Management LLC and Teachers Advisors LLC. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $112.40.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $23.88 billion and generates $7.82 billion in revenue each year. The medical equipment provider earns $1.81 billion in net income (profit) each year or $8.03 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is http://www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]

MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		643 (Vote Outperform)
Underperform Votes:		539 (Vote Underperform)
Total Votes:		1,182

MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 11/20/2018 by MarketBeat.com Staff